Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + fluorouracil + leucovorin + sargramostim

Development stage: Preclinical
Lead developer: Baxter
Modality: Small Molecules, Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

A combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline), fluorouracil (an antimetabolite), leucovorin (a reduced form of folate), and sargramostim (granulocyte-macrophage colony-stimulating factor). This combination is likely used in the treatment of advanced cancers, particularly breast cancer, with sargramostim added to support bone marrow recovery from the cytotoxic effects of the chemotherapy agents.

Targets

DNACSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + fluorouracil + leucovorin + sargramostim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + leucovorin + sargramostim.